Considering the dramatic drop of CD47 protein level after BCH treatment (Figs. 7e and 10b, c and Supplementary Fig. 17c), it is conceivable that the antitumor effect of BCH would be comparable with CD47 antibody treatment. Here, CD47 is linked to choreatic disease.